What is HC Wainwright’s Estimate for CTXR Q1 Earnings?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Citius Pharmaceuticals in a research note issued on Tuesday, November 12th. HC Wainwright analyst V. Bernardino anticipates that the company will earn ($0.05) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Citius Pharmaceuticals’ current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS and FY2026 earnings at $0.05 EPS.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01).

Citius Pharmaceuticals Price Performance

Citius Pharmaceuticals stock opened at $0.33 on Wednesday. Citius Pharmaceuticals has a one year low of $0.25 and a one year high of $1.07. The business’s fifty day moving average is $0.44 and its 200 day moving average is $0.60. The stock has a market capitalization of $59.35 million, a PE ratio of -1.61 and a beta of 1.66.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTXR. Point72 DIFC Ltd bought a new position in Citius Pharmaceuticals in the second quarter valued at about $29,000. BNP Paribas Financial Markets increased its position in shares of Citius Pharmaceuticals by 88.5% during the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after purchasing an additional 32,686 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Citius Pharmaceuticals in the 2nd quarter worth approximately $69,000. Arkadios Wealth Advisors boosted its holdings in shares of Citius Pharmaceuticals by 50.0% in the second quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company’s stock worth $88,000 after buying an additional 50,000 shares during the last quarter. Finally, Wealth Advisory Solutions LLC grew its position in Citius Pharmaceuticals by 33.1% during the third quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock valued at $101,000 after buying an additional 50,000 shares during the period. Institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.